ライフサイエンスコーパス: co-application

1 activation with hAmylin, Abeta1-42, or their co-application.

2 ssed below the control level during repeated co-applications.

3 Interestingly, the PNU-120596 agonist co-application data revealed that for wild-type alpha7 n

4 ddition, the polarity of the response to the co-application depends on the membrane potential of BF n

5 ippocampus and antagonized NIC response upon co-application implying partial agonist properties.

6 tes of modification were accelerated by GABA co-application, indicating that channel activation incre

7 At -40 mV the net effect of the co-application is inhibition by dynorphin-A, whereas at

8 BF neurons; at -40 mV the net effect of the co-application is inhibition by dynorphin-A, whereas at

9 Co-application of 0.01 to 67 mM BDM increased IGly decay

10 these currents significantly reduced by the co-application of 100 microM AMPA.

11 ed cells by recording the current induced by co-application of 30 mM potassium.

12 onal cell layers, which could be reversed by co-application of 5 mM lactate.

13 This was partly reversed by co-application of 5 mM lactate.

14 Responses caused by co-application of 5-HT (300 microM), acting at 5-HT3 rec

15 Co-application of 50 microM forskolin made the glycine-i

16 the LTD induction by serotonin + tetani, and co-application of a group I mGluR agonist and serotonin,

17 permeability increases could be prevented by co-application of a mixture of the antioxidants superoxi

18 Peak currents caused by co-application of ACh (1 mM) and ATP (300 microM) were 7

19 In outside-out membrane patches, co-application of ACh (4 microM) and VIP (4 nM) decrease

20 Reversal potentials measured during co-application of ACh and ATP did not differ from those

21 Co-application of alphabeta-MeATP (300 microM) with ATP

22 Co-application of amitriptyline or bupivacaine, which ta

23 Moreover, co-application of an anti-ASC antibody blocked the incre

24 Co-application of AP-5 and CNQX completely eliminated th

25 uced phase-shifts at ZT 10 are unaffected by co-application of baclofen.

26 The co-application of BAPTA (10 mM) with adenophostin blocke

27 17 activity can neither be accomplished with co-application of both ligand classes, nor with exogenou

28 Conversely, co-application of bradykinin or the P2Y-receptor agonist

29 rents, which were significantly increased by co-application of colominic acid.

30 We have previously shown that co-application of dopamine or the D2-like agonist quinpi

31 in-A desensitize over multiple applications, co-application of dynorphin-A and orexin-A produces a su

32 dynorphin-A and to orexin-A desensitize, but co-application of dynorphin-A and orexin-A produces a su

33 Intraplantar co-application of flagellin and QX-314 (flagellin/QX-314

34 In vivo electrophysiology demonstrated that co-application of flagellin/QX-314 selectively suppresse

35 the prominent membrane current rebound when co-application of GABA and CTZ was terminated suggests t

36 by a saturating concentration of GABA or by co-application of GABA and pentobarbital were recorded u

37 Currents were abolished by co-application of GABA with the GABA(A) receptor antagon

38 id ((RS)-CPP), and completely blocked by the co-application of GYKI 52466, 6-cyano-7-nitroquinoxaline

39 Co-application of HpSlyD and FK506 led to significant re

40 trifugal neurons, the eEPSCs were blocked by co-application of KYNA and MCM, whereas in the medulla n

41 Co-application of leptin (5 mug) and TRH (0.1 microg) to

42 Co-application of LTB4 and cholane steroid did not furth

43 Co-application of LTB4 with LTA4, LTC4, LTD4, or LTE4 su

44 Co-application of NE with ATP to resting microglia block

45 centrations of glycine, either alone or with co-application of NMDA, through a microdialysis probe im

46 Co-application of nociceptin and DADLE to neurons that w

47 Co-application of NT and AID peptide negated inhibitory

48 The effects of cPKA were blocked by co-application of PKA inhibitor (6-22) amide (PKI).

49 When treatment was done at 53 degrees C, the co-application of potassium sorbate with thiabendazole r

50 We found that co-application of retigabine strongly decreased the nico

51 +)DPAT, and this inhibition was decreased by co-application of tetrodotoxin.

52 amatergic and cholinergic receptors, because co-application of the glutamate antagonist kynurenic aci

53 on caused by DHPG (3 microM) was reversed by co-application of the mGlu receptor antagonist (+)-alpha

54 similar off-response is also observed after co-application of the negative modulator DHEAS and the p

55 pha4beta2-nAChR is significantly enhanced by co-application of the proinflammatory cytokine, tumor ne

56 tatory action of 8-OH-DPAT was attenuated by co-application of the selective 5-HT(1A) receptor antago

57 g fruit storage and were not affected by the co-application of thiabendazole.

58 mplitude), but these were not potentiated by co-application of up to 100 mM glycine.

59 The co-application of ZD 7288 and Ba2+ revealed a depolarizi

60 d the epidermal hyperplasia were reversed by co-applications of palmitic acid (but not linoleic acid)

61 ier homeostasis could be reversed by topical co-applications of the nonessential fatty acid, and of p

62 ays in barrier recovery can be overridden by co-applications of topical ceramide, demonstrating that

63 enuated the PM-induced inward current during co-application, providing further evidence that PDM func

64 Finally, flagellin/QX-314 co-application suppressed sodium currents in large-diame

65 0 microM carbachol was enhanced by the first co-application with 10 or 100 microM neostigmine, and th

66 it able to potentiate responses during brief co-application with the agonist.

67 ted but did not eliminate protection, whilst co-application with the NMDA receptor blocker MK-801 inc

68 Ligand co-applications with the positive allosteric modulator P